Clinical Trials Logo

Clinical Trial Summary

This dose finding, multi-cohort study is designed to evaluate the safety and efficacy of intradermally-injectedTNX-2100, synthesized SARS-CoV-2 peptide antigens and assess the presence and magnitude of DTH reactions.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05216510
Study type Interventional
Source Tonix Pharmaceuticals, Inc.
Contact
Status Active, not recruiting
Phase Phase 1
Start date January 7, 2022
Completion date August 2022